Risk Factors for Stress Urinary Incontinence During Rescue Radiation Therapy in Men with Recurrent Prostate Cancer after Surgical Treatment
Keywords:
Prostate Cancer, Biochemical Recurrence, Salvage Radiation Therapy, Stress Urinary Incontinence, Radiation Complications, Radical ProstatectomyAbstract
Stressful urinary incontinence is a significant complication of urinary incontinence in biochemical recurrence of prostate cancer, developing in every eighth patient. The dosage characteristics of radiation and radiation therapy techniques are modifiable risk factors. It is necessary to individualize the approaches to SLT, taking into account the initial status of the sphincter and the morphological parameters of the primary tumor.
References
[1] V. B. Matveev, B. P. Matveev, and B. V. Bukharkin, Prostate Cancer. Moscow, Russia: Verdana, 2020.
[2] S. B. Petrov and E. I. Veliyev, “Surgical treatment of localized forms of prostate cancer,” Practical Oncology, vol. 6, pp. 50–52, 2021.
[3] O. B. Loran and D. Yu. Pushkar, “Prostate-specific antigen and pathomorphological characteristics of prostate cancer,” Urology, no. 4, pp. 13–29, 2019.
[4] S. I. Tkachev, “Radiation therapy of prostate cancer,” in Clinical Oncourology, B. P. Matveev, Ed. Moscow, Russia: Verdana, 2013, pp. 525–546.
[5] E. B. Mazo, A. K. Chepurov, and O. V. Zorya, “Factors for predicting the progression of prostate cancer in patients after transurethral prostate resection,” in Proc. 2nd All-Russian Conf. Men’s Health, Moscow, Russia, 2015, pp. 179–180.
[6] I. N. Ognerubova, I. V. Poddubnaya, and V. B. Matveev, “The importance of the ultrasensitive method for quantitative determination of prostate-specific antigen in the diagnosis of prostate cancer recurrence,” Modern Oncology, no. 4, pp. 50–52, 2012.
[7] C. R. Pound, A. W. Partin, M. A. Eisenberger, et al., “Natural history of progression after PSA elevation following radical prostatectomy,” JAMA, vol. 281, pp. 1591–1597, 2019.
[8] A. V. D’Amico, R. Whittington, S. B. Malkowicz, et al., “Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer,” JAMA, vol. 280, pp. 969–974, 2018.
[9] G. E. Hanks, A. L. Hanlon, T. E. Schultheiss, et al., “Dose escalation with 3D conformal treatment: Five-year outcomes, treatment optimization, and future directions,” Int. J. Radiat. Oncol. Biol. Phys., vol. 41, pp. 501–510, 2018.
[10] M. Roach, A. Chen, J. Song, et al., “Pretreatment prostate-specific antigen and Gleason score predict extracapsular extension and risk of failure after radiotherapy,” Seminars in Urologic Oncology, vol. 15, pp. 109–114, 2020.
[11] R. B. Wilder, R. H. Choti, and J. K. Ryu, “Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: Preliminary results,” American Journal of Clinical Oncology, vol. 23, pp. 330–333, 2020.
[12] P. C. Walsh, A. W. Partin, and J. I. Epstein, “Cancer control and quality of life after anatomical radical retropubic prostatectomy: Results at 10 years,” Journal of Urology, vol. 152, pp. 1831–1836, 2024.
[13] B. Guillonneau and G. Vallancien, “Laparoscopic radical prostatectomy: The Montsouris experience,” Journal of Urology, vol. 163, pp. 418–422, 2000.
[14] T. A. Stamey, T. S. Sozen, C. M. Yemoto, et al., “Classification of localized prostate cancer and identification of high-risk disease,” Journal of Urology, vol. 159, pp. 2009–2012, 2018.
[15] F. Mottet et al., “EAU–ESTRO–ESUR–SIOG guidelines on prostate cancer,” European Urology, vol. 79, no. 2, pp. 243–262, 2021.
